Skip to main content
Wuhan Hiteck Biological Pharma Co.,Ltd logo

Wuhan Hiteck Biological Pharma Co.,Ltd — Investor Relations & Filings

Ticker · 300683 ISIN · CNE1000034C5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,111 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300683

About Wuhan Hiteck Biological Pharma Co.,Ltd

https://www.hiteck.com.cn

Wuhan Hiteck Biological Pharma Co., Ltd. specializes in the research, development, manufacturing, and commercialization of biopharmaceutical products. The company's flagship product is Mouse Nerve Growth Factor (mNGF) for injection, marketed under the brand name Enjingfu, which is primarily used for treating nerve damage and promoting nerve regeneration. Beyond its core focus on neurotrophic factors, the company explores therapeutic areas including oncology and cardiovascular diseases. Its operations encompass advanced biotechnological platforms for protein expression and purification. Hiteck emphasizes innovation in biological medicine, maintaining a portfolio of proprietary technologies and clinical-stage candidates aimed at addressing unmet medical needs in regenerative medicine and specialized therapeutic sectors.

Recent filings

Filing Released Lang Actions
北京高文（武汉）律师事务所关于公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 88% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm attesting to the legality of the company’s 2025 annual shareholders meeting procedures and containing the vote result details. It is not an AGM presentation (AGM-R), proxy solicitation (PSI), or the actual vote-results announcement (DVA) by the issuer but rather a legal attestation. Under the Certification Rule and per our fallback structure, this constitutes a miscellaneous regulatory/legal filing. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the 2025 Annual General Meeting resolutions for Wuhan Haite Biological, detailing attendance, vote counts, percentages, and the voting results on each agenda item. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-20 Chinese
关于获得注射用硫酸艾沙康唑药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is a routine corporate announcement disclosing that the company has received a drug registration certificate from the National Medical Products Administration. It contains product details, regulatory approval information, and a risk disclaimer, but does not present financial statements, meeting materials, voting results, or other specialized content. It’s a standard regulatory announcement to investors and the market. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-18 Chinese
关于董事辞职暨调整审计委员会成员的公告
Board/Management Information Classification · 98% confidence The document is an official announcement about the resignation of two board directors and the appointment of a new audit committee member, clearly detailing changes to the company’s board composition. This matches the definition of a Board/Management Information filing (Code: MANG).
2026-05-12 Chinese
第九届董事会第九次会议决议公告
Board/Management Information Classification · 90% confidence The document is a board meeting resolution announcement detailing director resignations and adjustments to the audit committee membership. It announces changes in the company’s board composition rather than providing financial data or regulatory filings. This aligns with the Board/Management Information category.
2026-05-12 Chinese
关于会计师事务所2025年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (auditor) for the fiscal year 2025. It discusses the auditor's qualifications, audit procedures, and the results of the audit for the company's 2025 financial statements, including internal control effectiveness and issuance of an unqualified audit opinion. The document is titled as an "evaluation report" on the auditor's performance rather than the audit report itself or the full annual report. It focuses on the auditor's role and assessment rather than presenting the company's financial statements or management discussion. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related audit information excluding full annual reports. The document length is short (1771 characters), but it contains substantive audit evaluation content, not just an announcement or certification. Therefore, the correct classification is AR with high confidence.
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.